Glitaray M 4 Forte Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride 4 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. This dual mechanism addresses hyperglycemia through complementary pathways, making Glitaray M 4 Forte effective in patients inadequately controlled by diet, exercise, and monotherapy. The prolonged-release formulation ensures steady plasma drug levels, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with Metformin. It is indicated for adult patients with type 2 diabetes who require combination therapy to achieve and maintain target blood glucose levels. Prior to initiation, renal function assessment is essential due to Metformin’s renal clearance and risk of lactic acidosis in impaired renal function. Patients should be monitored regularly for glycemic control, hypoglycemia, and potential adverse effects. Glitaray M 4 Forte should be used as part of a comprehensive diabetes management plan, including lifestyle modification. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to components.